Betegon L, Guilloteau I, Martin P, Woolmore A, Oyagüez I The relative value of dasatinib versus imatinib as first-line treatment for chronic myeloid leukemiay 15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012 POSTER
Betegon L, Guilloteau I, Martin P, Woolmore A, Oyagüez IBetegon L, Guilloteau I, Martin P, Woolmore A, Oyagüez I